Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVEENO Dermexa is a topical emollient cream formulated to moisturize, soothe, and protect very dry, itchy skin and skin prone to eczema. Its key active ingredients are a triple oat complex (colloidal oatmeal, oat oil, oat extract) and ceramides. The product works by strengthening the skin’s natural barrier function and helping restore its microbiome balance. Colloidal oatmeal acts as a skin protectant with anti-irritant and antioxidant properties; ceramides help maintain the integrity of the stratum corneum (outermost layer of the epidermis). The cream is fragrance-free, steroid-free, suitable for babies through adults—including those with sensitive or atopic-prone skin—and is clinically proven to relieve symptoms such as dryness and itching associated with eczema[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AVEENO Dermexa.